- $288.68bn
- $313.21bn
- $54.07bn
REG - AstraZeneca PLC - Baxfendy approved in the US for hypertension
AnnouncementREG - AstraZeneca PLC - Imfinzi + EV improves EFS & OS in bladder cancer
AnnouncementREG - AstraZeneca PLC - Total Voting Rights and Admission of Shares
AnnouncementREG - AstraZeneca PLC - FDA ODAC vote on camizestrant in breast cancer
AnnouncementREG - AstraZeneca PLC - FDA ODAC recommends Truqap in prostate cancer
AnnouncementREG - AstraZeneca PLC - 1st Quarter Results
AnnouncementREG - AstraZeneca PLC - Breztri approved in the US for asthma
AnnouncementREG - AstraZeneca PLC - Saphnelo self-administration approved in the US
AnnouncementREG - AstraZeneca PLC - Directorate change
AnnouncementREG - AstraZeneca PLC - I CAN PhIII interim analysis met primary endpoint
AnnouncementREG - AstraZeneca PLC - Third tozorakimab positive Phase III in COPD
AnnouncementREG - AstraZeneca PLC - Result of AGM
AnnouncementREG - AstraZeneca PLC - Imfinzi+Imjudo improves PFS in early liver cancer
AnnouncementREG - AstraZeneca PLC - Total Voting Rights and Admission of Shares
AnnouncementRCS - Brit Utd ProvAscBUPA - Bupa Announces Non-Executive Director Appointments
AnnouncementREG - AstraZeneca PLC - Efzimfotase alfa Ph3 program show positive results
AnnouncementREG - ConnectingExcellence - Appointment of Chief Performance & Growth Officer
AnnouncementREG - AstraZeneca PLC - Tozorakimab met OBERON/TITANIA primary endpoints
AnnouncementREG - AstraZeneca PLC - Notification of Admission of Shares
Announcement